Mucin expression and the pancreas: A systematic review and meta-analysis

Abstract

AIM

To assess mucin expression in pancreatic premalignant and malignant states, and to establish its role as a prognostic marker.

METHODS

English Medical literature searches were conducted for “mucin” and “pancreas”. Observational studies were included. Meta-analysis was performed by using Comprehensive meta-analysis software. Pooled odds ratios and 95%CIs were calculated.

RESULTS

Out of 949 eligible papers we found 20 according to the inclusion criteria, including 4262 patients, published till May 31, 2016. Mucin expression increased in pancreatic lesions with OR 10.206 (95%CI: 4.781-21.781, P < 0.0001). Measure of heterogeneity was high: Q = 296.973, df (Q) = 55.00, I² = 81.48%. We found a significant increase in the expression of MUC2, MUC4 and MUC5AC, 13.39, 118.43 and 13.91 times respectively, in pancreatic lesion in comparison with normal pancreatic tissue, and decreased expression of MUC5B.

CONCLUSION

Mucin expression may serve as prognostic marker for transformation of intraductal papillary mucinous neoplasms to ductal adenocarcinoma, for aggressiveness of the pancreatic tumor, and as targets for potential therapy.

Key Words: Mucin, Pancreas, Pancreatic cancer, Gene expression

Core tip: There is a higher mucin expression in intraductal papillary mucinous neoplasms (IPMN) and ductal pancreatic cancer. Mucin expression may be a bad prognostic factor. MUC2, MUC4, MUC5AC and probably MUC1, are expressed in IPMN advanced to ductal adenocarcinoma. These mucins are also bad prognostic factors for ductal adenocarcinoma.

INTRODUCTION

Mucins are high-molecular-weight glycoproteins, heavily glycosylated, synthesized and secreted by all mucosal surfaces of the human body and have an important role in healthy state and malignant diseases[1-3]. Change in mucins synthesis and secretion may be primary event or secondary to carcinogenesis or inflammation.

There are 21 known mucin genes in the human genome, encode for 2 types of mucins: Secreted and membrane-bound[4]. Membrane-bound mucins are involved in cell signaling and have a role in cellular processes such as growth, immune modulation, motility and adhesion.

Pancreatic carcinogenesis is associated with genetic and epigenetic changes, than may affect MUCs (mucin genes). MUCs may be expressed de novo during carcinogenesis. Mucins have potential value for diagnosis and follow-up of pancreatic neoplasms and for therapeutic interventions[5]. Mucin expression patterns may serve as a criterion for classification of intraductal papillary mucinous neoplasms (IPMN).

Several studies looked at mucins expression, comparing pancreatic lesions with normal pancreatic tissue. MUC1, membrane-bound mucin, is expressed in normal pancreatic tissue, but there is no detectable MUC2, MUC4 and MUC5AC[6,7].

Secretion of MUC1 is associated with adenocarcinoma and high grade dysplasia in pancreatic intraepithelial neoplasia (PanIN)[8-10]. MUC1 is rarely expressed in IPMN.

Positive expression of MUC2 in IPMN (intestinal type) indicates progression to carcinoma with secretion of MUC1[8,11]. Absence of MUC2 expression (gastric type) implies benign phenotype. MUC1 is rarely expressed in mucinous cyst in one study, while in another study mucinous cysts were found positive for MUC1/DF3[12,13].

MUC4 secretion correlates to the severity of dysplasia in PanIN and a poor prognosis in patients with adenocarcinomas, but results are somewhat inconsistent in different studies[14-17]. Expression of MUC4 in pancreatic cancer cell line was associated with increased proliferation, motility, adhesion, aggregation and metastasis[18].

The 2015 American Gastroenterological Association guidelines define 3 high-risk features of pancreatic cyst for developing cancer: Cyst size > 3 cm, dilated pancreatic duct and mural nodule[19]. There are no characteristics of mucin expression in the cyst fluid or the epithelial lining, as a marker for carcinogenesis.

The aim of this metaanalysis and systematic review is to assess the knowledge about mucin expression in pancreatic premalignant and malignant states, and to understand the possible role of mucin expressions as prognostic markers.

MATERIALS AND METHODS

Search strategy

Searches were conducted for “mucin” and “pancreas” through May 31, 2016, using MEDLINE, PubMed, Scopus, EMBASE, and CENTRAL. Hand searches of articles references were also performed. Only fully published human studies in English were included (Figure 1).

Figure 1 Flow chart of the articles identified for the meta-analysis.

Study selection

Observational studies about mucin expression in pancreatic tissue of cysts and adenocarcinoma were included. PRISMA guidelines for systematic reviews were strictly followed.

Data extraction

Author, country, year of publication, number of patients, and the number of positive staining were extracted. Data was stratified according to lesions (ductal adenocarcinoma, IPMN, mucinous cyst) and according to the mucin expressed (Table 1).

Table 1 Summary of mucin expression in pancreatic lesions.

Mucin gene	OR of mucin expression	P
MUC1	3.64	0.09
MUC2	13.39	0.05
MUC3	14.33	0.08
MUC4	118.43	< 0.001
MUC5AC	13.91	< 0.001
MUC5B	0.08	< 0.001
MUC6	0.52	0.41
MUC7	0	NA
Total mucin	9.99-21.72	< 0.001

OR: Odds ratio; NA: Not applicable.

Statistical analysis

Metaanalysis was performed by using Comprehensive metaanalysis software (Version 3, Biostat Inc., Englewood, NJ, United States). Pooled odds ratios and 95%CIs were calculated for mucin expression in pre-malignant and malignant pancreatic lesions. In all methods used (IMH, ISH or RT-PCR) OR represents quantitatively the number of patients with higher expression.

Heterogeneity was evaluated by Cochran Q-test, and considered to be present when Q-test P < 0.10. I² statistic was used to measure the proportion of inconsistency. We calculated publication bias using funnel plot of standard error by log odds ratio. Even distribution of the studies denied significant publication bias.

RESULTS

Out of 949 eligible papers we found 20 according to the inclusion criteria, including 4262 patients, published till May 31, 2016 from 4 countries (Japan 10, United States 9, France 1, Norway 1)[6,8,9,11-15,20-32] (Figure 1). There are 134 sub-studies (stratifying data according to mucin types and lesions). In 104 sub-studies immunohistochemistry (IMH) has been used, in 20 sub-studies RT-PCR for RNA, and in10 histochemistry. Eleven studies and 84 sub-studies had also results of normal pancreatic tissue for comparison with the neoplastic lesion. Ductal adenocarcinoma was examined in 14 studies and 60 sub-studies (2206 cases); IPMN was examined in 12 studies and 46 sub-studies (1691 cases). There were 365 cases of mucinous or colloid carcinoma, mucinous cystic neoplasm, hyperplastic pancreatic lesion, chronic pancreatitis and pseudo cysts. Funnel plot denies a significant publication bias (Figure 2).

Figure 2 Funnel plot for publication bias.

In the random-effect model, mucin expression was significantly higher in pancreatic lesions than in normal pancreatic tissue with OR 10.206 (95%CI: 4.781-21.781, P < 0.0001) (Figure 3). Measure of heterogeneity was high, demonstrated in the included studies: Q = 296.973, df (Q) = 55.00, I²= 81.48%. OR for mucin expression in pancreatic ductal adenocarcinoma and IPMN was 9.99 with 95%CI: 3.68-27.15, P < 0.001, and 21.72 with 95%CI: 4.01-117.55, P < 0.001, respectively (Figure 4). OR for expression in pancreatic lesion of MUC1- 4, MUC5AC, MUC5B, MUC6 and MUC7, was 3.64 with 95%CI: 0.80-16.49, P = 0.09; 13.39 with 95%CI: 1.03-173.43, P = 0.05; 14.33 with 95%CI: 0.742-95.97, P = 0.08; 118.43 with 95%CI: 19.39-723.48, P < 0.001; 13.91 with 95%CI: 2.35-82.14, P < 0.001; 0.08 with 95%CI: 0.02-0.36, P < 0.001; 0.52 with 95%CI: 0.11-2.47, P = 0.41; respectively (Figure 5). MUC7 was never expressed in pancreatic lesion or normal tissue (Table 1).

Figure 3 Metaanalysis of mucin expression in pancreatic lesions (20 studies, 134 sub-studies). PanIN: Pancreatic intraepithelial neoplasia; IPMN: Intraductal papillary mucinous neoplasms; STn: Sialyl Tn.

Figure 4 Meta-analysis of mucin expression in pancreatic lesions, sub-studies of different lesions. A: Ductal adenocarcinoma; B: Intraductal papillary mucinous neoplasm (20 studies, 102 sub-studies). PanIN: Pancreatic intraepithelial neoplasia; IPMN: Intraductal papillary mucinous neoplasms; STn: Sialyl Tn.

Figure 5 Meta-analysis of mucin expression in pancreatic lesions, sub-studies of different mucins. A: MUC1; B: MUC2; C: MUC3; D: MUC4; E: MUC5AC; F: MUC5B; G: MUC6 (17 studies, 104 sub-studies). PanIN: Pancreatic intraepithelial neoplasia; IPMN: Intraductal papillary mucinous neoplasms; STn: Sialyl Tn.

Studies description

Yamada et al[20] using histochemical methods compared the mucin expression between malignant and benign tumors of the pancreas. They found significant higher expression of sialomucin (> 50% of glands) in malignant tumors and higher expression of neutral mucin (> 50% of glands) in benign tumors. Osako et al[21] demonstrated a significant contrast between expression of mammary type mucin and intestinal type mucin in carcinomas and intraductal papillary tumor. The oncogenic mucin antigens, Tn and sialyl Tn (STn), were expressed in malignant and premalignant states but not in normal pancreatic mucosa. Incomplete glycosylation of mucins that results in expression of T, Tn, and sialyl-Tn antigens in pancreatic adenocarcinoma was described by Terada et al[13,32]. They found increased expression of Tn antigen and STn antigen in comparison with normal pancreatic tissue, but the same expression of MUC1 and T antigen. Similar findings were described for IPMN, which support the sequence of events from IPMN to adenocarcinoma. Yonezawa et al[8] found higher expression of MUC1 in ductal adenocarcinoma than IPMN, and lower expression of MUC2. Invasive growth areas of IPMN had MUC1 expression similar to adenocarcinoma. The same group demonstrated up regulation of MUC5AC mRNA in IPMN cases with a favorable prognosis, whereas such expression was not found in ductal adenocarcinoma cases with a poor prognosis[22].

Andrianifahanana et al[23] described a significant higher MUC4 expression in adenocarcinoma tissue than in chronic pancreatitis or normal pancreatic tissue. Lüttges et al[9] found expression of MUC2 in all IPMN and mucinous carcinoma cases of the pancreas but in only one of 35 of ductular adenocarcinoma cases. MUC1 expression was only demonstrated in ductular adenocarcinoma tissue. The same group also found strong expression of MUC5AC and MUC2 in mucinous cystic neoplasms of the pancreas, but no such expression of MUC1 and MUC6[12]. Kim et al[24] found a significant higher expression of MUC1, MUC5AC, Md2, STn antigen and sulpho Lewis a antigen in ductal adenocarcinoma of the pancreas than in normal pancreatic tissue. Swartz et al[14] found higher expression of MUC4 in invasive ductal adenocarcinoma of the pancreas than in PanIN. Expression was not demonstrated in normal pancreatic tissue. Nakamura et al[11] described 2 kinds of IPMN, according to MUC2 expression with higher invasive property for MUC2 positive than negative tumors. Terris et al[25] found increased expression of MUC5AC and MUC2 in IPMN, similar to colloid carcinoma, and different from ductal adenocarcinoma where MUC1 expression was increased. Horinouchi et al[6] found higher expression of MUC1 and MUC5AC in ductal adenocarcinoma than in IPMN. MUC2 was only expressed in IPMN of “dark phenotype”. Saitou et al[15] found a positive correlation between the strength of MUC4 expression in ductal adenocarcinoma of the pancreas and aggressive behavior. Such a correlation could not be demonstrated for MUC1. Kanno et al[26] found MUC4 and MUC5AC expression in adenoma and IPMN but not in normal or hyperplastic pancreatic tissue. Giorgadze et al[27] reviewed pancreatic 56 EUS-FNA specimens and 26 pancreatectomy specimens for expression profiles of MUC1, MUC2, MUC5AC and MUC6. MUC5AC expression was significantly higher in adenocarcinoma than in normal tissue both in EUS-FNA specimens and surgical specimens. Westgaard et al[28] found that in adenocarcinoma MUC1 and MUC4 expression was associated with a poor prognosis. Gonzalez Obeso et al[29] used alcian blue and mucicarmine stains in 11 pseudo cysts and 42 IPMNs or mucinous cysts aspirates. They could not demonstrate a significant difference in mucin staining between the various types of cysts. Streppel et al[30] found MUC16 (CA125) expression in 81.5% of 200 pancreatic adenocarcinoma tissues, in comparison with none of 29 IPMN cases and in 2% of normal pancreatic tissues. Kitazono et al[31] looked at the expression rates of MUC4 in intestinal-type IPMNs and gastric-type IPMNs using monoclonal antibodies 8G7 and 1G8. The expression rate of MUC4 in the intestinal-type IPMNs was higher than in the gastric-type IPMNs. Maker et al[33] examined 40 cases of pancreatic IPMN comparing mucin expression in cases with high risk IPMN (with high grade dysplasia or carcinoma) and cases with low risk IPMN (with low grade dysplasia). They found a significant increase in MUC2 and MUC4 expression (10.0 ± 3.0 ng/mL and 20.6 ± 10.6 ng/mL vs 4.4 ± 1.2 ng/mL and 4.5 ± 1.4 ng/mL, P = 0.03, respectively). No change was demonstrated for MUC1 and MUC5AC. This study is not included in the metaanalysis since numerical data is absent and only means of mucin expression are given.

DISCUSSION

Mucin is an important component of the mucus layers protecting epithelial surfaces of the respiratory, digestive, urinary and reproductive organs, and as such was studied intensively. The role of mucin in exocrine/endocrine gland such as the pancreas is less understood. Most of the studies about pancreatic mucin expression involved malignant transformation and characteristics of pancreatic cysts. In Table 1 we summarized the knowledge about mucin expression in the pancreas, including the findings of our metaanalysis.

In our metaanalysis we found a significant increase in the expression of MUC2, MUC4, and MUC5AC, 13.39, 118.43 and 13.91 times respectively, in pancreatic lesion in comparison with normal pancreatic tissue (Table 1), and decreased expression of MUC5B. The results for MUC1, MUC3, MUC6, Tn and STn were not statistically significant.

Exploring individual studies some different and inconsistent finding are presented, but it is obvious that higher malignant behavior of IPMN and transfer into ductal adenocarcinoma is characterized by increased expression of MUC2, MUC4 and MUC5AC[9,12-15,20,21,23,26-28,33]. The expression of these mucins in the ductal adenocarcinoma implied a bad prognosis. MUC1 expression, even though did not reach significance in the metaanalysis, was also a marker for bad prognosis in ductal adenocarcinoma[8,24,28].

IPMN could be originates from the pancreatic main duct, or side-branches, being of gastric type (MUC5AC is expressed in dark cells) or of intestinal type (MUC2 is expressed in clear cells). Gastric IPMNs are MUC1 and MUC2 negative, usually located in the branch small ducts, and rarely develop into cancer. Intestinal IPMNs are MUC1 negative but MUC2 positive. However, when they transform into cancer, the MUC1 becomes positive. They are mostly located in the main duct. MUC4 expression in IPMNs may help to distinguish intestinal IPMNs from the safer gastric-type IPMNs.

Our meta-analysis has some limitations, since the methods of mucin expression measurement, and the definition of the pancreatic lesion may be inaccurate. There is heterogeneity regarding detection of mucin expression and disease classification. In some studies immunohistochemistry was used for protein detection and in other RT-PCR or in situ hybridization for RNA detection. The definition of pancreatic mucinous cyst and side-branch or main-duct IPMN (Previously IPMT) also was changed during the last decade, and the results of different mucins expression in different lesions should be taken with caution. Also PanIN (pancreatic intra epithelial neoplasia), the pancreatic gland equivalent of adenomatous change or dysplasia, has been never studied in the context or mucin genes expression.

In conclusion, expression of MUC2, MUC4, MUC5AC and probably MUC1, may serve as prognostic marker for transformation of IPMN to ductal adenocarcinoma, for aggressiveness of the pancreatic tumor, and as targets for potential therapy. Further studies are needed to establish these observations.

COMMENTS

Background

Pancreatic carcinogenesis is associated with genetic and epigenetic changes, that may affect mucin genes. Certain mucins are expressed during carcinogenesis, while specific patterns have been recognized in pre-malignant and malignant lesions.

Research frontiers

Assessing mucin expression in pancreatic premalignant and malignant states, and to establish its role as a prognostic marker.

Innovations and breakthroughs

Mucin expression was higher in pancreatic lesions than in healthy pancreatic tissue: OR 10.206 (95%CI: 4.781-21.781, P < 0.0001).

Applications

The author found a significant increase in the expression of MUC2, MUC4 and MUC5AC, 13.39, 118.43 and 13.91 times respectively, in pancreatic lesion in comparison with normal pancreatic tissue, and decrease expression of MUC5B.

Peer-review

This is a very good paper, with a large amount of interesting data and work. The analysis is conducted respecting the protocols of meta-analysis.